Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
May 24, 2019 1:46 PM 3 min read

Secondary Offerings Put A Pause On May's Momentum

by Ross Cameron - Warrior Trading
Follow

After a strong first half to the month, our May momentum has started to peter out this week, which is part of the reason I’m unfortunately still short on my weekly $10,000 goal.

This isn’t too disappointing since I remain green on the week and—because of the strong follow-through early in the month—solidly above my monthly benchmark. Nevertheless, the abrupt change in the market we’ve seen this week has been frustrating.

During Thursday’s recap, I touched on why I think an excess of secondary offerings might be part of the reason for the faltering momentum. Four of the stocks I traded in the week, Can Fite Biopharma ADR (NYSE:CANF), Obalon Therapeutics Inc. (NASDAQ:OBLN), MYnd Analytics Inc. (NASDAQ:MYND) and OncoSec Medical Inc. (NASDAQ:ONCS) each announced a secondary offering.

Funny enough, I successfully traded three of these stocks prior to their offering, making a little more than $8,000 between the three of them. But, my trades in ONCS, which was moving on a 10-for-1 reverse split, unfortunately cut into that by $4,700.

The net effect of these offerings is more share supply, less demand and a growing reticence amongst traders to buy into cheaper stocks like CANF and OBLN for fear of getting caught in a news halt and losing their shirts.

It’s fortunate that I did trade these names when I did and was able to watch the sell-off from the offering after I was out of the position.

My Monday trades in CANF (the leading gapper on my premarket scanner that day) was really the only strong momentum play of the week. I entered my first position with about 7000 shares at the break of the premarket high for my first trade, took a small loss on a broken one-minute setup, then made one final trade on a five-minute break above the previous candle that did follow-through that eventually pushed it to a high-of-day 70 percent above its previous close.

Two hours later, the stock was halted and the company announced a $6 million direct offering. CANF finished the day lower by 36 percent.

Which explains why, on Tuesday, on a very similar setup in ONCS, there wasn’t as much enthusiasm to trade the move. I took a large position as the stock was exiting a circuit-breaker halt, but ended up buying near the top of the move just above $5 and getting stopped out. I took another trade as it squeezed back up with the same result.

ONCS remained in that range the whole day before falling on Wednesday’s open after, you guessed it, the company announced a secondary offering.

While I’m never happy to take a loss, particularly of that size, Tuesday’s red day sent a clear signal that the market winds were changing, and I needed to change with them. I posted a couple of small green days Wednesday and Thursday, and I plan on remaining cautious on Friday.

Adjusting your risk isn’t simply about the characteristics of the stock your trading, but the temperament of the traders with which you’re competing.

Warrior Trading is a content partner of Benzinga.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
EducationPsychologyMarketsGeneralWarrior Trading
CANF Logo
CANFCan Fite Biopharma Ltd
$4.05-10.6%
Overview
MYND Logo
MYNDMynd.ai Inc
$0.44902.05%
CANF Logo
CANFCan Fite Biopharma Ltd
$4.05-10.6%
Overview
MYND Logo
MYNDMynd.ai Inc
$0.44902.05%
Comments
Loading...